MedTrace Logo

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

NCT02634008 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2022-08-22

No results posted yet for this study

Summary

An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.

Conditions

  • Hepatitis C, Acute

Interventions

DRUG

Paritaprevir/ritonavir/ombitasvir

DRUG

Dasabuvir

DRUG

Ribavirin

DRUG

Glecaprevir/pibrentasvir

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Gail Matthews, MBBS PhD · Kirby Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Australia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02634008 on ClinicalTrials.gov